[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

5 clusters · 13 sources · 14 days · First seen · Last updated

STAREE trial and evolving cholesterol treatments

Overview

The STAREE trial, a large-scale clinical study involving nearly 10,000 participants from Australian general practices, has demonstrated that daily atorvastatin significantly reduces the risk of major cardiovascular events in healthy adults aged 70 and older.

Findings published in the New England Journal of Medicine indicate a 30 per cent reduction in the risk of cardiovascular death, nonfatal myocardial infarction, stroke, and coronary revascularization among participants with no prior history of cardiovascular disease, diabetes, or dementia. In absolute terms, this represented a reduction of approximately 2 to 3 events per 100 people treated over a median follow-up of 5.9 years. While the medication successfully lowered cardiovascular risks, researchers noted that it did not significantly improve mortality, dementia, or disability-free survival.

Recent research has also expanded the understanding of cholesterol management. While statins inhibit cholesterol synthesis, studies into PCSK9 inhibitors, such as evolocumab and alirocumab, highlight their role in treating severe hypercholesterolemia. These inhibitors work by blocking a liver-produced protein, increasing the liver’s ability to remove LDL cholesterol from the bloodstream, offering an alternative for patients unable to reach therapeutic targets through statins alone.

Additionally, scientists at the University of British Columbia and the University of Wisconsin–Madison have identified a potential biological cause for statin-induced muscle pain. Using cryo-electron microscopy, they discovered that statins may attach to the RyR1 protein, disrupting calcium levels necessary for muscle function. This aligns with observations from the STAREE trial, where musculoskeletal issues were slightly more frequent in the atorvastatin group than in the placebo group.

Entities

New England Journal of Medicine · European Society of Cardiology · Monash University · Mark Nelson · University of British Columbia

Timeline

  1. 3 days ago

    [HEALTH] 2 sources
    Medical studies clarify benefits of cholesterol treatments for seniors and high-risk patients

    Medical studies confirm that statins reduce cardiovascular risks in adults over 70 by 30%, while PCSK9 inhibitors offer an alternative for managing severe LDL cholesterol levels.

  2. 4 days ago

    [HEALTH] 2 sources
    Statins: New insights into muscle pain causes and cardiovascular benefits

    New research explores why statins cause muscle pain via the RyR1 protein, while a major trial shows the drugs reduce cardiovascular events in adults over 70 by 30% despite no impact on disability-free survival.

  3. 12 days ago

    [HEALTH] 4 sources
    Monash University study finds statins reduce heart risk in seniors

    A decade-long Monash University study found that daily statins reduce the risk of major cardiovascular events by 30% in healthy adults over age 70.

  4. 16 days ago

    [HEALTH] 2 sources
    STAREE trial finds atorvastatin reduces cardiovascular events in older adults

    The STAREE trial found that atorvastatin reduces major cardiovascular events by 30% in adults aged 70+ without prior disease, though it did not significantly improve disability-free survival.

  5. 16 days ago

    [HEALTH] 2 sources
    Monash University study finds statins reduce heart attack risk in adults over 70

    A Monash University study found that statins reduce heart attack and stroke risk by 30 per cent in healthy adults over 70, providing new evidence for preventative care in older populations.

Sources

consultantlive.com · elbalad.news · farmacoecura.it · knowridge.com · medicaldialogues.in · microbiologiaitalia.it · optimistdaily.com · sawt-alasima.net · theage.com.au · theguardian.com · time.news · womensweekly.com.au · ye-voice.com

This summary has been updated 4 times: see revision history